Status:
UNKNOWN
18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology
Lead Sponsor:
University of Manitoba
Collaborating Sponsors:
Winnipeg Regional Health Authority
Conditions:
Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test \[Positron Emission Tomography (PET)scan\] in adults who have or are suspected of having canc...
Eligibility Criteria
Inclusion
- Known or suspected primary or metastatic tumours
- A neurological presentation consistent with the list of indications
- 18 years of age or older of either sex
- Able to provide written informed consent
- Able to tolerate the physical and logistical requirements of completing a Positron Emission Tomography (PET)scan
- Karnofsky score \> 60
- Women who are nursing may be included in the study if they are able to discontinue breast feeding for 12 hours
Exclusion
- Age \<18 years
- Pregnant women; if there is a possibility of pregnancy, bloodwork will be drawn to definitively establish pregnancy status
- Women who are unwilling or unable to discontinue breast feeding for 12 hours post 18F-Fluorodeoxyglucose(FDG) administration
- Subjects who are medically unstable
- Subjects unwilling to provide informed consent.
- Subjects who exceed the safe weight limit of the Positron Emission Tomography (PET) imaging bed or who cannot fit through the PET scanner bore
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2013
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT01180751
Start Date
July 1 2010
End Date
December 1 2013
Last Update
August 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Great West Life PET/CT Centre
Winnipeg, Manitoba, Canada, R3E 3P4